esmo 2021: parpi data and their role in mono/combination therapies
Published 2 years ago • 135 plays • Length 35:58Download video MP4
Download video MP3
Similar videos
-
2:18
#esmo21 highlights on maintenance olaparib in ovarian cancer previously treated with parpi
-
4:44
expert report on survival data from pivotal trials with parp inhibitors for brca-mut. ovarian cancer
-
6:16
asco 2021 - highlights on shifting parpi to early breast cancer: the olympia study
-
0:58
data on parp inhibitor treatment in ovarian cancer presented at esmo
-
1:41
parp inhibitors at the crossroads in ovarian cancer: 2022 esmo florida
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
38:47
parp inhibitors and their evolving role for the treatment of prostate cancer
-
35:35
maximizing the potential of parp inhibitors as first-line maintenance therapy in ovarian cancer
-
1:25
dr. emens on the combination of checkpoint inhibitors and parp inhibitors in ovarian cancer
-
59:14
parp inhibitors in ovarian cancer: clinical updates from sgo 2023
-
6:25
combinations with parp inhibitors for ovarian cancer
-
2:51
#esmo21 highlights on adagrasib in patients with krasg12c-mutated crc: the krystal-1 study
-
57:11
personalizing advanced ovarian cancer treatment with parp inhibitors and novel approaches
-
2:38
assessing the role of parp inhibitors and immunotherapy in ovarian cancer
-
4:12
parp inhibitors
-
8:29
esmo 2019: dr. mirza on important trials with parp inhibitors in ovarian cancer
-
4:40
solo-1 and parp inhibitors in ovarian cancer
-
3:44
the future role of parp inhibition in ovarian cancer
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer